CDMOs
CDMOs
Scinai Launches US Subsidiary to Boost Biotech
**Excerpt:** 🌟 Scinai Immunotherapeutics launches Scinai Bioservices in Delaware! 🚀 Enhancing CDMO services and collaborating with Serpin Pharma. 💼🔥
Mastering Advanced Therapies: Key Insights for Success!
Unlock the secrets of advanced therapy processes! 🧬 Early insights and GMP alignment are essential for success. 📝💡
Powerful Pharma Partnership Boosts US Manufacturing!
🌟 Recipharm and Exela Pharma join forces! 🏭 This alliance boosts sterile manufacturing in the U.S. 💉 Exciting biopharmaceuticals ahead! 📈🤝
Unlocking Biotech: Why CDMOs Must Embrace Innovation!
🌍 CDMOs must showcase new bioprocessing tech benefits to win over clients. 💰 Larger firms hesitate, while smaller ones embrace innovation. 🤝
2024’s Top CDMOs: Leaders and Challenges Ahead!
**Excerpt:** Discover the top 10 CDMOs for 2024! 🌟 Lonza, Thermo Fisher, and Catalent lead the way amidst industry challenges. 📈⚠️
Agilent’s $925M Biovectra Buy: Boosting Growth!
Agilent is acquiring Biovectra for $925M! 💰 This deal enhances CDMO services, especially in mRNA and gene editing. 🚀📦
Revolutionary Company Solves Manufacturing Failures for Gene Therapy
📢 Introducing Bespark*bio: Tackling manufacturing failures in gene therapy to bring life-saving treatments to the market! 🏭💡💉
CDMO Incog Supercharges Operations with $75M Expansion
🔧 CDMO Incog gears up with 💰$75m expansion to boost filling capacity. Exciting times ahead! 🚀🔬👩🔬 pharmaceuticals growth
CDMO Leadership Shuffles: Impact on Biotech
📌 Explore the impact of leadership shuffles at CDMOs in the biotech industry 🌍🔬. Find out why stability matters!
Biogen’s CDMO Revenues Set to Plummet!
📢 Biogen, a global biotech company, anticipates a decline in CDMO revenues as its Denmark commitments conclude. 😔
